Immune Pharmaceuticals Inc (fka IMNPQ)

[Investor100]

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) lost about -56.1 percent in value since last earnings

http://theindependentrepublic.com/2016/11/07/immune-pharmaceuticals-inc-nasdaqimnp-lost-about-56-1-percent-in-value-since-last-earnings/

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) is projected to declare fiscal third quarter financial results right before the stock market’s official open on November 16, 2016. The stock lost about -56.1 percent in price since last results when it was at $0.41 a share. Based on the most relevant past-periods data, there is an 80 percent probability for this firm’s share price to go down following next quarterly results. Earnings reaction history tells us that the equity price moved down 4 times out of last 5 reported quarters. It has beaten earnings-per-share estimates 33% of the time in its last 12 earnings reports. It fell short of earnings estimates on 6 occasions, and it has met expectations 1 time.

Here’s how traders responded to IMNP earnings announcements over the past few quarters.

Immune Pharmaceuticals, Inc. (IMNP) Earnings Surprises & Reaction

Given its history, the average earnings announcement surprise was -865.4 percent over the past four quarters. Back on August 15, 2016, it posted earnings per-share earnings at $-0.13 which beat the consensus $-0.14 projection (positive surprise of7.14%. For the quarter, revenue came in at 0M versus consensus estimate of 0M. The stock dropped -4.88 percent the session following the earnings reports were released, and on 7th day price change was -7.32 percent.

On May 16, 2016, it reported earnings at $-0.17 a share compared with the consensus estimate of $-0.17 per share (negative surprise of 0%). Revenue of 0M for that quarter was below the $0M analysts had expected. The stock climbed 11.11% the day following the earnings announcement, and on 7th day price change was 0%.

On November 12, 2015, it announced earnings per share at $-0.33 versus the consensus estimate of $0.01 per share (negative surprise of -3400%). That came on revenues of $0M for that period. Analysts had expected $0M in revenue.

Immune Pharmaceuticals, Inc. Earnings Estimates

As Q3 earnings announcement date approaches, Wall Street is expecting earnings per share of $-0.13. The analysts’ present consensus range is $-0.15-$-0.11 for EPS. The market consensus range for revenue is between $0M and $0M, with an average of $0M.

Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) last ended at $0.18, sending the company’s market cap near $15.3M. The consensus 12-month price target from analysts covering the stock is $2. The share price has declined -88.05% from its top level in 52 weeks and advanced -74.79% this year. It recently traded at a volume of 1162574 shares. The recent trading ended with the price nearly -17.45 lower for the last 5 trading days, rebounding 10.25% from its 52-week low.

investor 100